Lundbeck rejects talks of crisis and brings this year's third drug to the clinic
For the third time in 2018, the pharmaceutical company Lundbeck begins clinical trials with a brand new potential drug. It is another self-developed drug, which makes Executive Vice President at Lundbeck, Anders Gersel Pedersen, reject criticism against the company's pipeline.
On Monday, the more than 100-year old pharmaceutical company Lundbeck issued another highly effective response to the critical voices that have expressed concern about the company's pipeline of potential drugs.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Lundbeck sees blockbuster potential in new acquisition
For abonnenter
